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Chronic progressive renal disease: Rate of change of serum con-
centration. The rate of change of the serum creatinine concentra-
tions in 63 patients with chronic progressive renal disease of varied
etiology was examined by linear regression analysis using the loga-
rithm or the reciprocal of the serum creatinine concentration ver-
sus time. A single straight line was described by one or the other of
these relationships in 53 patients. Six patients had an accelerated
rate of nephron destruction terminally (two slopes) regardless of
the mathematical analysis. The remaining four patients had course
changes either due to apparent spontaneous remissions or tempo-
rally related to therapy. These data suggest that (functional) neph-
ron loss in chronic progress disease is orderly and mathematically
definable. The theoretical implications are that functional nephron
loss is either exponential (log Cr) or constant (I/Cr).
Maladie rénale chronique évolutive: Vitese de Ia modification de Ia
créatinine du serum. La vitesse de modification de Ia concentration
de créatinine du serum chez 63 malades atteints d'affections rénales
chroniques évolutives d'étiologies diverses a été étudiCe par
analyse de Ia regression Iinéaire du logarithme ou de l'inverse de Ia
créatinine sérique en fonction du temps. Une ligne droite unique
est obtenue pour l'une u l'autre de ces relations chez 53 malades.
Six malades ont eu une vitesse de destruction des néphrons aug-
mentée a Ia phase terminale (deux pentes) indépendamment de
l'analyse mathématique. Les qoatre derniers malades ont eu des
modifications de l'évolution soit dues a des remissions apparem-
ment spontanées OU coThcidant dans Ic temps avec un traitement.
Ces résultats suggèrent que Ia perte de néphrons (fonctionnels)
dans les affections chroniques progressives est réglée et définissable
mathCmatiquement. Les implications theoriques sont que Ia perte
de néphrons functionnels est soit exponentielle (log Cr) soit con-
stante (I/Cr).
Early descriptions of the natural history of renal
(Bright's) disease stressed the widely held view that
chronic progressive disease was the sequel of an in-
fectious process — streptococcal [1—6]. Remissions
and exacerbations were considered part of the natural
course and it was thought that various diseases
passed through or among phases or stages. These
descriptions implied erratic courses and diagnostic
uncertainty compounded the complexity.
Later, safe percutaneous renal biopsy techniques
permitted histopathologic diagnostic certainty; sub-
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sequent accounts of the natural history of various
chronic renal diseases resolved some issues. Gross
correlation was established between histology and the
rate of disease progression, e.g. extraglomerular pro-
liferation (subacute or rapidly progressing glome-
rulonephritis) was associated with rapid deteriora-
tion of function [7], thickening of the basement
membrane (membranous glomerulonephritis) corre-
lated with relatively slower rates of progression [8],
and some diseases (lipoid nephrosis) progressed very
little, if at all [8]. These studies implied a degree of
orderliness; nevertheless, pathologically similar le-
sions were associated with dissimilar rates of progres-
sion. They suggested that histologic similarity might
not mean disease homogenity and/or that any dis-
ease, in a given host, could have different rates of
progression; and they also underscored the need to
quantitate rate.
We observed that the rate of change in serum
creatinine concentration in individual patients with
chronic progressive renal disease was extremely or-
derly and that rate could be quantitated using simple
linear regression analysis. Straight line relationships
have been found between time and the logarithm
and/or the reciprocal of the serum creatinine concen-
tration. Mitch and Walser simultaneously made
similar observations [9].
Methods
The medical records were screened of patients ad-
mitted to the Washington University chronic hemo-
dialysis program or attending the Barnes Hospital
and St. Louis City Hospital renal clinics. All records
which contained at least four serum creatinine deter-
minations with a minimum range of 2.0 mg/dl
between the lowest and the highest values (z creati-
nine) were singled out for review.
Patients were assigned to the following five groups
according to the etiology of their renal disease:
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Table 1. Numerical data calculated from linear regression analysis of serum creatinine concentration vs.
time in patients with progressive renal disease
Section a: Logarithm of creatinine Section b: ReciprocaI of creatinine
Patient No. of ob- Correlation s Doubling Correlation SE 10% reduc-
no. servations Slope coefficient estimate time, months Slope coefficient estimate tion time
Glomerulonephrilis
7 0.01037 0.98195 0.00604 29.04 —0.00914 0.96038 0.01533 10.94
0.15374 1.00000 1.96
2 38 0.01827 0.96988 0.03127 16.47 —0.01490 0.98032 0.02044 6.71
0.09560 0.95841 0.05880 3.15 —0.02589 0.98524 0.00929 3.86
3 18 0.02155 0.99083 0.03158 13.97 —0.01986 0.97934 0.04659 5.04
0.06033 0.89373 0.07332 4.99
4 34 0.00706 0.96433 0.05358 44.80 —0.01334 0.98860 0.03797 7.50
0.02233 0.98035 0.02869 13.29
0.11439 0.92724 0.09638 2.69
5 48 0.00704 0.94967 0.06875 42.75 —0.00747 0.93765 0,08006 13.39
0.07500 0.97708 0.04977 4.01 —0.02060 0.99146 0.00825 4.85
6 20 0.00261 0.98056 0.01825 115.43 —0.00261 0.98202 0.01753 38.31
0.02894 0.94951 0.08454 10.40 0.01 124 0.98589 0.01688 8.90
Diabetes mellitus
7 4 0.04413 0.98269 0.05404 6.82 —0.05060 0.97049 0.08167 1.98
8 34 0.04248 0.98836 0.05204 7.06 —0.02687 0.91825 0.04743 3.72
—0.00950 0.97516 0.01029 10.53
9 39 0.02298 0.93816 0.04781 13.10 —0.02356 0.06790 0.03513 4.24
0.08468 0.96919 0.05589 3.55
10 14 0.00391 0.84386 0.03247 76.93 —0.00770 0.86558 0.04080 12.99
0.02464 0.86714 0.05739 12.22
11 62 0.01266 0.77403 0.08331 23.70 —0.01387 0.71992 0.10990 7.21
0.10824 0.87588 0.09085 2.78 —0.03803 0.80521 0.04258 2.63
12 11 0.01099 0.99877 0.01407 27.40 —0.00725 0.99587 0.01090 13.79
0.04207 0.98862 0.02897 7.15
13 8 0.00756 1.00000 39.80 —0.00907 0.99148 0.03439 11.03
0.0367! 0.961 10 0.08604 8.20
14 13 0.00363 0.88515 0.04586 82.84 —0.00339 0.87534 0.04499 29.50
Pyelonephritis
IS 5 0.03809 0.92927 0.04124 7.90 —0.01434 0.94919 0.01295 6.97
16 16 0.01085 0.95696 0.02965 27.73 —0.00568 0.97813 0.01729 17.61
0.04357 0.82718 0.09750 6.91
17 17 0.01725 0.97730 0.03930 17.45 —0.00980 0.97696 0.02473 10.20
0.01284 0.98743 0.03524 2.34
18 17 0.00342 0.71852 0.03940 88.09 —0.00145 0.85889 0.01313 68.97
0.02352 0.98823 0.01203 12.80
19 24 0.00390 0.72131 0.04710 79.16 —0.00137 0.73339 0.01636 72.99
20 14 0.00002 0.01311 0.02486 —0.00001 0.01713 0.00860
0.01713 0.94696 0.06626 17.57 —0.00364 0.97513 0.00942 27.47
21 17 0.00884 0.99115 0.01472 34.04 —0.00463 0.98739 0.00922 21.60
22 47 0.00292 0.90826 0.04393 102.97 —0.00134 0.92974 0.01744 74.63
0.0 1336 0.86745 0.02874 22.53
Polycystic renal disease
23 16 0.00768 0.89150 0.03400 39.21 —0.00146 0.86853 0.00724 68.49
24 5 0.01037 0.90237 0.04733 29.04 —0.00259 0.90555 0.01162 38.61
25 9 0.01081 0.98961 0.01582 27.86 —0.00374 0.99754 0.00265 26.74
26 25 0.00536 0.93069 0.03171 56.15 —0.00118 0.92879 0.00706 84.75
27 25 0.01657 0.22397 0.04505 18.16 —0.06294 1.00000 1.59
—0.01273 0.99906 0.00715 7.86
—0.00489 0.98075 0.00947 20.45
28 21 0.00733 0.88397 0.03600 41.07 —0.00707 0.89866 003203 14.14
29 14 0.00788 0.98851 0.07255 38.21 —0.00595 0.99467 0.01846 16.81
0.02208 0.96151 0.02827 13.64
Miscellaneous
30 5 0.02703 0.96278 0.00438 11.14 —0.01579 0.96200 0.01157 6.33
33 —0.00127 0.09120 0.00248 0.00025 0.03878 0.02424 cx
15 0.04989 0.91796 0.00598 6.03 —0.0122! 0.94443 0.0115! 8.19
31 19 0.00289 0.64626 0.05436 104.01 —0.00178 0.63492 0.03452 56.18
6 0.05923 0.99474 0.01717 5.08 —0.01821 0.9830! 0.00958 5.49
5 —0.04043 0.83970 0.03992 0.01091 0.86849 0.00888
6 0.03125 0.98051 0.02360 9.63 —0.00673 0.97828 0.00538 14.86
32 9 —0.01037 0.87409 0.05298 0.00419 0.89288 0.01943
9 0.01042 0.97119 0.05098 28.90 —0.00305 0.96174 0.01735 32.79
33 6 0.08893 0.93029 0.07053 3.38 —0.07834 0.96322 0.04396 1.28
18 —0.00128 0.56641 0.02400 0.00104 0.54684 0.02096
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Table 1. (Continued)
Section a: Logarithm of creatinine Section b: ReciprocaI of creatinine
Patient No. of ob- Correlation SE Doubling Correlation s 10% reduc-
no. servations Slope coefficient estimate time, months Slope coefficient estimate tion time
Unknown
34 12 0.02676 0.98233 0.01742 11.25 —0.00432 0.96636 0.00393 23.15
35 7 0.03213 0.95520 0.02983 9.37 —0.00639 0.94593 0.00657 15.65
36 37 0.04899 0.96797 0.04695 6.14 —0.01493 0.96881 0.01411 6.70
37 12 0.01240 0.88429 0.02576 24.27 —0.00232 0.87402 0.00507 43.10
38 14 0.05962 0.95908 0.05005 5.05 —0.01794 0.96454 0.01396 5.57
39 12 0.01765 0.97254 0.02739 17.05 —0.00379 0.97338 0.00578 26.39
40 12 0.01612 0.90283 0.04802 18.67 —0.00334 0.92015 0.00888 29.94
41 28 0.00567 0.83815 0.04178 53.05 —0.00129 0.83259 0.00971 77.52
42 17 0.00406
0.02615
0.56657
0.64169
0.06984
0.07329
74.17
11.51
—0.00177 0.55488 0.03142 56.50
43 18 0.00579 0.74407 0.05252 52.02 —0.00130 0.72277 0.01260 76.92
44 24 0.01080 0.77631 0.07638 27.89 —0.00324 0.82882 0.01905 30.77
45 25 0.00750
0.02 147
0.88499
0.96702
0.04152
0.02446
40.16
14.02
—0.00276 0.95231 0.00934 36.23
46 28 0.00487 0.75110 0.05982 61.82 —0.00096 0.74659 0.01198 104.17
47 29 0.01146
0.01570
0.84751
0.92190
0.04803
0.06981
26.26
19.18
—0.00534 0.97175 0.02566 18.73
48 15 0.00267
0.06595
0.50266
0.96152
0.02901
0.04492
113.70
4.56
—0.00476
—0.01613
0.90891
0.97900
0.00058
0.00799
21.01
6.20
49 10 0.01810 0.87557 0.03359 16.64 —0.00432 0.91877 0.00624 23.15
50 19 0.01218 0.97188 0.03519 24.72 —0.00649 0.97189 0.01875 32.80
51 13 0.00970
0.02008
0.95617
0.97569
0.00133
0.04556
31.04
14.99
—0.00820 0.98630 0.03003 12.19
52 22 0.00847
0.01369
0.96409
0.92915
0.03644
0.04165
35.54
21.99
—0.00292 0.94413 0.01672 35.46
53 23 0.10455 0.95557 0.07782 2.88 —0.11335 0.88098 0.14691 0.88
54 17 0.02440 0.92480 0.03529 12.34 —0.01176 0.88043 0.02227 8.50
55 29 0.01020
0.03446
0.78461
0.95439
0.00762
0.04735
29.53
8.74
—0.00524 0.84577 0.03943 19.08
56 17 0.00722 0.84311 0.05481 41.71 —0.00392 0.81660 0.03299 25.51
57 18 0.00401 0.76590 0.04334 74.99 —0.00214 0.77399 0.02251 46.73
58 30 0.00207 0.63014 0.04537 145.68 —0.00115 0.63499 0.02484 86.96
59 28 0.00709
0.03634
0,96649
0.98358
0.04657
0.01811
42.44
8.28
—0.00843 0.96139 0.06930 11.86
60 26 0.00697 0.61387 0.09308 43.18 —0.00564 0.68349 0.06250 17.73
61 10 0.00824 0.92480 0.07081 36.54 —0.00752 0.93903 0.05754 13.30
62 10 0.00480 0.69306 0.05 169 62.66 —0.00482 0.65982 0.05674 20.75
63 21 0.02786 0.50013 0.15059 10.80 —0.04608 0.57909 0.20252 2.17
glomerulonephritis, adult-onset diabetes mellitus,
pyelonephritis, polycystic renal disease, and diseases
of unknown etiology.
Five of six patients classified as glomerulonephritis
had biopsy—proven disease. The patient lacking
biopsy confirmation had hereditary nephritis by his-
tory and clinical findings. Patients with an abnormal
glucose tolerance test, characteristic of diabetes mel-
litus (prior to the onset of renal impairment), were
presumed to have diabetic renal disease. Polycystic
renal disease was established in seven patients on the
basis of family history, physical findings and in-
travenous pyelography. Patients were considered to
have pyelonephritis if there was a history of recurrent
urinary tract infection documented by at least two
cultures growing greater than 108 colonies/mi of a
pathogenic organism and evidence of scarring or con-
traction of one or both kidneys on intravenous pyelo-
graphy. Most of these patients had obstructive ur-
opathy. Two patients meeting these criteria were
placed in the unknown group since they excreted
greater than 3 gm of protein per 24 hours. Patients
with hypertension as the only suspected etiology of
their disease were assigned to the unknown group.
Patients with collagen vascular diseases are not rou-
tinely followed in the renal clinics, and only one
patient with systemic lupus erythematosis was in-
cluded in this study (patient 30).
The date of the first recorded determination of
serum creatinine concentration was designated arbi-
trarily as the zero time. All other values were assigned
a time corresponding to the nearest tenth of a month
relative to time zero.
The line of regression formed by the points repre-
senting the logarithm of the serum creatinine concen-
tration (log Cr) or the reciprocal of the serum creati-
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nine concentration (1/Cr) was plotted automatically
using a Hewlett-Packard 9810 computer with 9862A
plotter.
If visual inspection of the data suggested more than
one slope, each was analyzed separately. The slopes
were considered significantly different by the Stu-
dent's t test [10].
The relationship between creatinine and time was
expressed by the equations log Cr = bi + log a or
1/Cr = bi + a; where Cr = serum creatinine concen-
tration in mg/dl, I = time in tenths of months, b =
the slope, and a = the y intercept. The coefficients a
and b were calculated by linear regression [10]
adopted for the logarithm or the reciprocal of the
serum creatinine concentration. The time required
for the serum creatinine concentration to double (re-
ferred to as the doubling time, in months) was calcu-
lated from the linear regression. Similarly, the time
required for the reciprocal of the serum creatinine
concentration to decrease by one tenth (referred to as
the 10% reductioq time, in months) was also calcu-
lated from the linear regression.
The data from all patients are plotted as log Cr and
1/Cr versus time. The lines determined by linear re-
gression analysis for each patient are presented in
mass plots according to diagnostic categories. Slope
(b), standard error of the estimate (SE Est) and corre-
lation coefficient (r), are listed in Table 1. Detailed
data from two patients are illustrated in Figure 1.
Patient 59 (Fig 1, IA and B) is a representative ex-
ample of the scatter of points around the line. Patient
11 (Fig. 1, hA and B) is an example of the worst fit
of points about the lines. Numerical data for each
line are listed in the legend. Detailed data from other
patients illustrating particular points are shown in
Figures 5—9. By relating both the r and SE Est (Table
1) to the plots of individual patients (Figs. 1, 5—9),
one can then appreciate what the scatter of points
would be about the lines shown in the mass plots. The
scale dependence of the SE Est prevents comparisons
between the log and the reciprocal scales.
Mass plots of the lines representing the courses of
all patients are shown in Figures 2—4. Patients with
glomerulonephritis had courses outlined by two or
more slopes on the semilog plot (Fig. 2, IA). Half of
these patients (2, 5 and 6) also had two slopes on the
reciprocal plot (Fig. 2, IB). Individual points for
patients 4 and 6, illustrating the two different patterns
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E
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12 24 36 12 24 36
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Fig. 1. Semilogarithm (A) and reciprocal (B) plots on two patients (I
and II) with lines calculated by linear regression from individual
serum creatinine concentrations and time. Patient 59 (I, A and B)
had chronic glomerulonephritis (presumed) with an initial slope (b,)
on the A plot of 0.00709; sv Est1 = 0.04657; and r, = 0.96649. The
second slope (b,) = 0.03634; SE Est2 = 0.01811; and r2 = 0.98358.
The slope (b1) on the B plot was —0.00843; SE Est, = 0.06930; and
r, = 0.96139. Patient 11(11, A and B) had maturity onset diabetes
mellitus with wide fluctuations in serum creatinine concentrations
during hospitalizations for congestive heart failure and ketoaci-
dosis. For the A plot, SE Est, = 0.08331; SE Est2 = 0.09085; b, =
0.01266; b2 = 0.10824; r, = 0.77403; and r, = 0.87588. for the B
plot, b1 = 0.01387; b2 = —0.03803; SE Est, = 0.10990; SE Est2 =
0.04258; r, = 0.71992; and r, = 0.80521.
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Fig. 2. Mass plots of the relationship between time and the logarithm
of the serum creatinine concentration (A) and the reciprocal of the
serum creatinine concentration (B) versus time in patients with
glomerulonephritis (I) and diabetes mellitus (II).
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Fig. 5. Individual data and calculated lines for two patients with
courses described by two rates of progression. A single straight line is
drawn on the reciprocal plot (I B) illustrating the course of patient
48 to demonstrate the difficulty in detecting a second slope on this
plot. The slope of the line formed by the first seven points is
statistically different from that found by the last eight points. The
course of patient 6 (Il, A and B) is characterized by two slopes
which is obvious on either plot.
vidual data for each are shown in Figure 7 (I, A and
B) and Figure 1 (II, A and B), respectively. Data
from patients with pyelonephritis (Fig. 3, IA and B)
include one patient (patient 20) with two distinct
slopes on both plots. Almost all patients with poly-
cystic renal disease had courses described by single
S
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Fig. 3. Semilogarithrn (A) and reciprocal (B) plots of the courses of
patients with pyelonephritis (I) and polycystic renal disease (II).
of progression, are also shown in Figure 6 (II, A and
B) and Figure 5 (II, A and B), respectively. Most
patients with diabetes mellitus had courses outlined
by two slopes on the semilog plot (Fig. 2, hA) and a
single straight line on the reciprocal plot (Fig. 2, IIB).
Patients 8 and 11 have contrasting courses and mdi-
8A lB
1
12 24 36 48 :
UIA
E
20
10
5
20
Fig. 4. Semilogarithm (A) and reciprocal (B) plots 0/the courses of
patients with renal disease of unknown etiology.
Time, months Time, months
Fig. 6. Patient 27(1, A and B) and patient 4 (II. A and B) illustrate
the different patterns predicted by each model. Numerical data are
listed in Table I.
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Fig. 7. Patient 8 (1, A and B) and patients 29 (II, A and B). The
patterns probably would have been like those in Figure 6 if data
had been available very early in the course. Numerical data are
listed in Table 1.
straight lines (Fig. 3, hA and B). Two patients in this
group (Patients 27 and 29) had courses best described
by a change in slope. Individual data for these
patients are presented in Figure 6 (I, A and B) and
Figure 7 (II, A and B), respectively. The data for
patients with unknown or undocumented etiology are
shown in Figure 4. This group also contains patients
with courses characterized by two slopes. Individual
20 IA
,V to lB
10
6 12 18 24
C0 in lB
E
25(I,
0.5
244872
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Fig. 8. Patient 30 (1, A and B) with mixed membranoproliferarive
glomerulonephritis treated with cyclophosphamide (2 mg/kg of body
wt). Patient 31(11, A and B) with proliferative lupus nephritis was
also treated with cyclophosphamide (2 mg/kg of body wt). The
arrows delineate the treatment period. The change in slope in all
cases was highly significant.
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Fig. 9. Two patients with unique courses. Patient 32 (1, A and B) had
acute anuric renal failure following abruptio placentae. Hemo-
dialysis was discontinued after three months, time zero, and
reinstituted after more than six years. Patient 33 (II, A and B) had
membranoprohiferative glomerulonephritis with crescents on all
glomeruli. Renal function deteriorated rapidly early in the course.
Prednisone (1 mg/kg of body wt) and cyclophosphamide (2mg/kg
of body wt) were administered during the time outlined by the
arrows. Therapy was discontinued when the patient developed
pneumonia and therapy seemed ineffective. Gradual improvement
ensued over the subsequent four years.
data for patients 48 arid 59 are shown in Figure 5 (I,
A and B) and Figure 1 (1, A and B), respectively.
Patients with two slopes describing the progression
of their renal disease on either plot were distributed
throughout all disease categories. Patients with a
straight line outlining their course on both plots were
individuals for whom only a segment of their courses
were known.
Four patients had distinctive courses (Figs. 8 and
9). Two patients (Fig. 8) had therapeutic intervention
coincidental with changes in slope. Two others (Fig.
9) appeared to have spontaneous remissions of their
disease process.
Discussion
It is well established that progressive renal failure is
associated with a commensurate increase in the se-
rum creatinine concentration [11—14], and since a
constant inverse relationship exists between the se-
rum creatinine concentration and endogenous creati-
nine clearance [13, 15], and since the clearance of
creatinine approximates glomerular filtration rate
[13, 15, 16], and since, in the absence of disease, there
is a direct relationship between glomerular filtration
rate and nephron number [17], one could argue that a
straight line relationship between the logarithm of the
20
10
5
24 48 72
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24 48 72 96 24 48 72 96
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Fig. 10. Two mathematical models in which the serum creatinine
Concentrations increase from I to 20 mg/dl in 95 months. If the
serum creatinine concentration doubled at a constant rate, a single
straight line relationship would be observed as in IA and a curve
illustrated by three straight lines, in lB. Conversely, if the reciprocal
of the serum creatinine concentration decreases at a constant rate,
a straight line relationship will be obtained in IIB and a curve
illustrated by three straight lines in hA.
serum creatinine concentration and time suggests
that nephrons are lost at a constant fractional rate,
i.e., the time required for the serum creatinine con-
centration to double should be equal to the time
required for the loss of 50% of the nephron popu-
lation (creatinine doubling time T 1/2 for nephron
destruction). By the same reasoning, a straight line
relationship between the reciprocal of the serum
creatinine concentration and time suggests that neph-
rons are lost at a constant rate.
In disease there may or may not be a direct rela-
tionship between glomerular filtration rate and neph-
ron number. In some models of experimental renal
failure, single nephron glomerular filtration rate in-
creases [18—21] and tubular cells hypertrophy [22]. In
others, single nephron glomerular filtration rates de-
crease [23]. For these reasons it should be understood
that the reference to nephrons is to function: the
definition is operational, and the rate of nephron loss
is mathematically defined in this sense.
Both models are illustrated in Figure 10 to facil-
itate comparison. A single straight line predicted by
one model predicts a curve by the other. The sim-
ilarities between the models and the data from
patients 4, 8, 27 and 29 are obvious (Figs. 6 and 7). In
each case a single straight line is described by one
model or the other. A similar pattern is observed
(Fig. 11) when data from Goldstein [24] is plotted
according to the format used in this paper. A single
straight line is drawn on each plot because of the
limited number of points. Nevertheless, the points on
the reciprocal plot appear to form a curve as the
model would predict. Analysis of this sort is only
possible when data is available throughout most of
the course. If the period of observation in patient 4
had been confined to the time indicated by the second
slope (Fig. 6, IIA), both models would have predicted
a single straight line relationship with a low SE esti-
mate and a high correlation coefficient (Table I).
Furthermore, if the period of observation in patient
0.1
.05
24 36
Time, months
Fig. II. Mean serum creatinine concentrations from 112 juvenile
onset diabetic patients at various times after the detection of diabetes
as reported by Goldstein 124J. Mean creatinine concentrations of
1.2, 2.8, 8.5 and 12.4 mg/dl were observed at 17.3, 19.4, 21.6 and
22.1 years, respectively, after the detection of abnormal glucose
metabolism. 17.3 years was chosen as time zero and time there-
after expressed in months. These data plotted on the log plot (A)
where b = 0.01741, r = 0.99643, and sv Est = 0.04778. On the
reciprocal plot (B), b = —0.01283, r 0.97993, and SE ESt =
0.08460.
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27 (Fig. 6, IA and B) had been confined to the last 18
months it might have been (we would have) con-
cluded that her course was best described by two
straight lines on a semilogarithm plot and a single
straight line on a reciprocal plot. The opposite con-
clusion is reached after reviewing all the data.
A single straight line was described by the relation-
ship between the serum creatinine concentration and
time, using one mathematical model or the other, in
53 of 63 patients. In some, a single straight line was
described by both equations. This was true when the
period of observation was short, the creatinine was
small (less than 6 mg/dl), the slope was greater than
0.022 (semilog plot), or the first recorded serum
creatinine concentration exceeded 7.5 mg/dl.
Six patients (2, 5, 6, 11, 20 and 48) had an accelera-
ted rate of nephron destruction terminally, regardless
of the mathematics used for analysis (Fig. 1—5). There
was no obvious cause for the change in slope in those
patients with two slopes. Hypertensive crises were
conspicuously absent. The mean diastolic blood pres-
sure during the terminal slope in patient 6 was signifi-
cantly higher than the first; however, in no other
patient was there any correlation between diastolic
blood pressure and slope (P> 0.40) or any difference
between the mean diastolic blood pressure during the
first slope compared to the second (P > 0.70). Even
though there is ample evidence that hypertension has
deleterious effects on renal function [25, 26], the data
suggest that hypertension is not responsible for in-
itiating or maintaining the terminal slope. Further-
more, the change in slope was not associated with
congestive heart failure, febrile illness, or weight
change.
Two patients (patients 32 and 33) had unique
courses with apparent spontaneous remissions. The
courses were described equally well by both models.
The remaining two patients (patients 30 and 31) had
courses which were temporally related to therapeutic
interventions, and these data suggest that a patient
could serve as his/her own control in a therapeutic
trial. Analysis of this sort permits statistical arbi-
tration of efficacy. Furthermore, figures 2 through 4
illustrate the difficulties inherent in using any group
of patients as controls since patients with the same
disease have diverse courses.
If the rate of disease progression in any patient is
constant, then an alteration in course temporally re-
lated to therapy could be considered causal though
this does not establish a cause and effect relationship.
This assumption requires a priori knowledge about
which patient will or will not have more than one rate
of progression and which mathematical model to use.
The varied rates of progression among patients with
the same disease suggest that individual host factors
are important. Furthermore, the courses of patients
27 and 29 suggest that individual host factors rather
than diseases determine which model will more likely
predict a single straight line.
The decision regarding which model to use or to
apply in any given situation, therefore, must be made
on a practical basis. A model which defines a single
straight line relationship between the serum creati-
nine and time would be preferred because of its sim-
plicity. One might choose model B because more
patients had courses described by a single straight
line on the reciprocal plot than on the logarithm
plot. However, in those patients with two apparent
rates of progression the second slope may be harder
to detect on the reciprocal plot as illustrated by
patient 48 (Fig. 5, IA and B). The reason is obvious;
the reciprocal of a large number is a small fraction.
Therefore, if the desire is to predict the time when
transplantation or dialysis would be required, the log
plot might be most useful since the second slope
would be easier to detect. After the second slope has
begun, predictions may be made with confidence.
If the desire is to follow the course of patients in a
therapeutic trial, it might be better to plot the data on
semilogarithm coordinates in order to avoid inter-
preting an ineffective regimen as being beneficial. If
the serum creatinine concentrations, which would
predict a straight line by log Cr = bt + log a, were
plotted on a reciprocal plot, the points would de-
scribe a course which could erroneously be inter-
preted as two slopes (Fig. 10) or be misinterpreted in
a therapeutical trial as a beneficial effect. For ex-
ample, if therapy had been administered to patient 27
(Fig. 6, IB) any time between the 6th and 24th
months, one might have erroneously concluded that
the regimen beneficially affected the course of her
disease.
It is concluded that nephron function may be lost
at a constant rate or a constant exponential rate. The
theoretical concepts of functional nephron loss have
been derived mathematically. The underlying path-
ophysiology remains to be defined experimentally.
The determination of which mathematical model to
apply prospectively to any given patient remains to
be defined.
Acknowledgments
This work was supported by National Institutes of
Health, Division of Research Sources, grant RR
00036, and Public Health Service grant AM 09976.
The authors acknowledge the help of Dr. John Kis-
sane who reviewed all biopsy material. Miss Patti
Lyles provided secretarial assistance.
70 Rutherford et a!
Reprint requests to Dr. W. E. Rutherford, Department of Medi-
cine, Washington University, School of Medicine, 1515 Lafayette
Avenue, St. Louis, Missouri 63104, U.S.A.
References
1. ELLIS A: Natural history of Bright's disease: III. The vicious
cycle in chronic Bright's disease. Lancet 1:72—76, 1942
2. ADDIs T: A clinical classification of Bright's disease. JAm Med
Assoc 85:163—167, 1925
3. ADDIS T: The renal lesion in Bright's disease. Am J Med Sci
176:617—637, 1928
4. VAN SLYKE DD, STILLMAN E, MALLER E, EHRICH W, Mclr.t-
TOSH JF, LEITER L, MACKAY EM, HANNAN RR, MooRE NS,
JOHNSTON C: Observations on the courses of different types of
Bright's disease, and on the resultant changes in renal anat-
omy. Medicine 9:257—386, 1930
5. Lor'tacopa WT: Some observations on the course and out-
come of hemorrhagic nephritis. Trans Am C/in Climatol Assoc
53:153—171, 1937
6. VOLUARD F, FAHR T: Die Brightsche Nierenkrankheit, Berlin,
Springer—Verlag, 1914
7. BACANI RA, VELASQUEZ F, KANTER A, PIRANI CL, POLLACK
VE: Rapidly progressive (nonstreptococcal) glomerulone-
phritis. Ann Intern Med 69:463—485, 1968
8. POLLACK VE, ROSEN S, PIRANI CL, MUEHRCHE RC, KARK
RM: Natural history of lipoid nephrosis and of membranous
glomerulonephritis. Ann Intern Med 69:1171-1196, 1968
9. MITCFI WE, WALSER M: The effect of nutritional therapy on
progression of chronic renal failure: quantitative assessment
(abstr.). Cliii Res 24:407, 1976
10. COLTON T: Statistics in Medicine. Boston, Little, Brown and
Company, 1974, pp. 189—218
II. MILLER BF, LEAF A, MANIBY AR, MILLER Z: Validity of the
endogenous creatinine clearance as a measure of glomerular
filtration rate in the diseased kidney. J Clin Invest 3 1:309—313.
1952
12. TOBIAS GJ, MCLAUGHLIN RF, HOPER J: Endogenous creati-
nine clearance: a valuable clinical test of glomerular filtration
and a prognostic guide in chronic renal disease. N Engi J Med
226:317—323, 1962
13. LUBOWITZ H, SLATOPOLSKY E, SHANKEL S, RIESELBACH RE,
BRICKER NS: Glomerular filtration rate. JAm MedAssoc 199:
252—256, 1967
14. HOLTEN C. REHBERG PB: Studies on the pathological function
of the kidneys in renal disease, especially Bright's disease. II.
Acta Med Scand 74:538—565, 1931
IS. DOOLAN PD, ALPEN EL, THEIL GB: A clinical apprasial of the
plasma concentration and endogenous clearance of creatinine.
Am J Med 32:65—79, 1962
16. ROI-IBERG PB: Studies on kidney function: I. The rate of filtra-
tion and reabsorption in the human kidney. fbchem J
20:447—460, 1926
17. ORLOWSKI T, BRICKER NS: The relationship between renal
function and the direct glomerular count in normal dogs. Acta
Med Pol 5:246—256, 1964
18. LUBOWITZ H, PURKERSON M, SUGITA M, BRICKER NS: GFR
per nephron and per kidney in chronically diseased (pyelo-
nephritic) kidney of the rat. Am J Physiol 217:853—857, 1969
19. BANK N, AYNEDJIAN HS: Individual nephron function in ex-
perimental bilateral pyelonephritis: 1. Glomerular filtration
rate and proximal tubular sodium potassium, and water reab-
sorption, J Lab C/in Med 68:713—727, 1966
20. BRICKER NS, KLAHR S, RIESELBACH RE: The functional adap-
tation of the diseased kidney: I. Glomerular filtration rate.
J Clin Invest 43:1915—1921, 1964
21. MAZUMDAR DC, CROSSON JT, LUB0wITz H: Glomerulotubu-
lar relationships in glomerulonephritis. J Lab C/in Med
85:292—299, 1975
22. HAYSLETT JP, KASHGARIAN M, EPSTEIN FH: Functional cor-
relates of compensatory renal hypertrophy. J C/in Invest 47:
774—782, 1968
23. LUBOWITZ H, MAZUMDAR DC, KAWANURA J, CROSSON JT,
WEISSER F, ROLE D, BRICKER NS: Experimental glomerulo-
nephritis in the rat: structural and functional observa-
tions. Kidney Int 5:356—364, 1974
24. GOLDSTEIN HH: The problem of end-stage diabetic nephrop-
athy. Kidney mt 6 (suppl 1):S2l—S23, 1974
25. SoKoLow M, PERLOFF D: The prognosis of essential hyperten-
sion treated conservatively. Circulation 23:697—713, 1961
26. VA Cooperative Study Group on Antihypertensive Agents:
Effects of treatment on morbidity: III. Influence of age, dia-
stolic blood pressure, prior cardiovascular disease: Further
analysis of side effects. Circulation 45:991—1004, 1972
